Browsing Tag

biophamaceutical

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1…

Jason Junior Oct 20, 2021

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T…

Health

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for…

Jason Junior Oct 13, 2021

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor…

Health

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform…

Jason Junior Jun 15, 2021

• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting…